BlueRock Therapeutics’ President and CEO Seth Ettenberg, Ph.D. talks to Cell & Gene: The Podcast listeners about the company’s Phase 1 Clinical Trial for Advanced Parkinson’s Disease. Ettenberg also covers the most promising therapeutic applications for iPSCs currently in development as well as the major regulatory challenges that the field faces for their clinical use. We also cover how far iPSCs have come and what future progress may entail.
Related News
Press Releases
BlueRock Therapeutics investigative cell therapy bemdaneprocel for treating Parkinson’s disease receives Pioneering Regenerative Medical Product designation in Japan
December 17, 2025
Press Releases